- The risk for colorectal cancer (CRC) was higher with sulphonylureas (except gliclazide) in patients with type 2 diabetes mellitus (T2DM).
- Long-term follow-up studies are warranted for information on the association between newer antidiabetic medications and CRC risk.
Why this matters
- There is no clarity whether CRC risk among patients with T2DM originates from hyperglycaemia itself or antidiabetic medications or both.
- Population-based, nested case-control study on a prospective cohort provided by the National Health Insurance Corporation (2007-2014) was performed.
- The study identified patients with newly diagnosed T2DM with (cases, n=4228) or without CRC (matched controls, n=4228).
- Funding: the Korea government.
- An increasing trend for CRC risk with increasing cumulative doses of sulphonylurea was noted (aOR, 1.14; 95% CI, 1.05-1.25; Pfor trend=.0008).
- The risk for CRC increased in patients ≥65 years (aOR, 1.23; 95% CI, 1.06-1.42) but not in patients
- The risk for CRC among patients using sulphonylurea drugs:
- decreased with gliclazide (aOR, 0.85; 95% CI, 0.72-1.00; P<.0550>
- increased with glimepiride (aOR, 1.14; 95% CI, 1.06-1.22); and
- Data on glycated haemoglobin not captured.
- Single measurement of glucose (fasting plasma glucose) was used to compare data.